Literature DB >> 30647879

Screening of the Pathogen Box reveals new starting points for anti-trypanosomal drug discovery.

Clinton G L Veale1, Heinrich C Hoppe2.   

Abstract

This study aimed to uncover new starting points for anti-trypansomal drug discovery through the screening of the Pathogen Box against Trypanosoma brucei brucei. Our study identified compounds 35, 39, 46, 53 and 56 whose activity and selectivity highlighted them as promising candidates with potential for further study and optimisation.

Entities:  

Year:  2018        PMID： 30647879      PMCID： PMC6301270          DOI： 10.1039/c8md00319j

Source DB:  PubMed          Journal:  Medchemcomm        ISSN： 2040-2503            Impact factor:   3.597


  10 in total

1.  An Antiparasitic Compound from the Medicines for Malaria Venture Pathogen Box Promotes Leishmania Tubulin Polymerization.

Authors:  Imran Ullah; Suraksha Gahalawat; Laela M Booshehri; Hanspeter Niederstrasser; Shreoshi Majumdar; Christopher Leija; James M Bradford; Bin Hu; Joseph M Ready; Dawn M Wetzel
Journal:  ACS Infect Dis       Date:  2020-07-20       Impact factor: 5.084

2.  Characterization of Entamoeba histolytica adenosine 5'-phosphosulfate (APS) kinase; validation as a target and provision of leads for the development of new drugs against amoebiasis.

Authors:  Fumika Mi-Ichi; Takeshi Ishikawa; Vo Kha Tam; Sharmina Deloer; Shinjiro Hamano; Tsuyoshi Hamada; Hiroki Yoshida
Journal:  PLoS Negl Trop Dis       Date:  2019-08-19

3.  A screening of the MMV Pathogen Box® reveals new potential antifungal drugs against the etiologic agents of chromoblastomycosis.

Authors:  Rowena Alves Coelho; Luna Sobrino Joffe; Gabriela Machado Alves; Maria Helena Galdino Figueiredo-Carvalho; Fábio Brito-Santos; Ana Claudia Fernandes Amaral; Marcio L Rodrigues; Rodrigo Almeida-Paes
Journal:  PLoS One       Date:  2020-05-13       Impact factor: 3.240

4.  Development of Novel Isoindolone-Based Compounds against Trypanosoma brucei rhodesiense.

Authors:  Daniel G Silva; Pim-Bart Feijens; Rik Hendrickx; An Matheeussen; Lucie Grey; Guy Caljon; Louis Maes; Flavio S Emery; Anna Junker
Journal:  ChemistryOpen       Date:  2021-09       Impact factor: 2.911

5.  In vitro growth inhibitory activity of Medicines for Malaria Venture pathogen box compounds against Leishmania aethiopica.

Authors:  Markos Tadele; Solomon M Abay; Peter Asaga; Eyasu Makonnen; Asrat Hailu
Journal:  BMC Pharmacol Toxicol       Date:  2021-11-16       Impact factor: 2.483

6.  Temporal and Wash-Out Studies Identify Medicines for Malaria Venture Pathogen Box Compounds with Fast-Acting Activity against Both Trypanosoma cruzi and Trypanosoma brucei.

Authors:  Melissa L Sykes; Emily K Kennedy; Kevin D Read; Marcel Kaiser; Vicky M Avery
Journal:  Microorganisms       Date:  2022-06-25

7.  Preliminary Structure-Activity Relationship Study of the MMV Pathogen Box Compound MMV675968 (2,4-Diaminoquinazoline) Unveils Novel Inhibitors of Trypanosoma brucei brucei.

Authors:  Darline Dize; Rolland Bantar Tata; Rodrigue Keumoe; Rufin Marie Kouipou Toghueo; Mariscal Brice Tchatat; Cyrille Ngansop Njanpa; Vianey Claire Tchuenguia; Lauve Tchokouaha Yamthe; Patrick Valere Tsouh Fokou; Benoît Laleu; James Duffy; Ozlem Tastan Bishop; Fabrice Fekam Boyom
Journal:  Molecules       Date:  2022-10-04       Impact factor: 4.927

8.  Leishmania donovani Growth Inhibitors from Pathogen Box Compounds of Medicine for Malaria Venture.

Authors:  Markos Tadele; Solomon M Abay; Eyasu Makonnen; Asrat Hailu
Journal:  Drug Des Devel Ther       Date:  2020-03-31       Impact factor: 4.162

9.  Synthesis, Structure and In Vitro Anti-Trypanosomal Activity of Non-Toxic Arylpyrrole-Based Chalcone Derivatives.

Authors:  Ayanda I Zulu; Ogunyemi O Oderinlo; Cuan Kruger; Michelle Isaacs; Heinrich C Hoppe; Vincent J Smith; Clinton G L Veale; Setshaba D Khanye
Journal:  Molecules       Date:  2020-04-04       Impact factor: 4.411

10.  Repurposing the Pathogen Box compounds for identification of potent anti-malarials against blood stages of Plasmodium falciparum with PfUCHL3 inhibitory activity.

Authors:  Hina Bharti; Aakriti Singal; Manisha Saini; Pradeep Singh Cheema; Mohsin Raza; Suman Kundu; Alo Nag
Journal:  Sci Rep       Date:  2022-01-18       Impact factor: 4.379
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.